文献速递临床试验与 GCP基础与转化研究

补充胆碱预防和治疗早期缺铁所致学习和记忆缺陷(SupCHO研究):一项在乌干达缺铁性贫血婴儿中开展的随机安慰剂对照试验的研究方案

Supplemental choline to prevent and treat learning and memory deficits of early-life iron deficiency (The SupCHO Study): study protocol for a randomized, placebo-controlled trial in Ugandan infants with iron deficiency anemia.
PubMed 文献 · Trials · 2025-11-19

该研究为在乌干达6月龄缺铁性贫血婴儿中开展的随机安慰剂对照试验方案,计划纳入300名婴儿,随机接受铁剂联合胆碱或铁剂联合安慰剂,铁剂口服硫酸亚铁2 mg/kg/天共3个月,胆碱(酒石酸氢胆碱200 mg)或安慰剂每日服用共9个月,在入组时和随访9个月后评估海马依赖性记忆、注意及整体认知。

要点

  • 6月龄缺铁性贫血婴儿随机接受铁剂联合胆碱或铁剂联合安慰剂。
  • 铁剂口服硫酸亚铁2 mg/kg/天共3个月,胆碱200 mg/天或安慰剂共9个月。
  • 在6月龄和15月龄评估海马特异性记忆、注意及整体认知。

核心结论

  • 若发现胆碱联合铁剂带来神经行为获益,胆碱可立即加入缺铁性贫血的标准治疗。

研究设计与样本

  • 随机、安慰剂对照临床试验,计划纳入300名6月龄缺铁性贫血婴儿,在乌干达坎帕拉Mulago和Kawempe国家转诊医院的免疫接种门诊招募。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 铁剂为口服硫酸亚铁2 mg/kg/天,在随访前3个月给予。
  • 胆碱为酒石酸氢胆碱200 mg分散片或相同安慰剂,每日给予,共9个月随访期。
  • 在入组时(6月龄)和随访9个月后(15月龄)进行神经行为测试,评估海马特异性记忆和注意及整体认知。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iron deficiency (ID) limits the neurodevelopmental potential of more than 200 million children each year. Iron therapy started when IDA is first diagnosed-typically by screening for anemia or detection of clinical symptoms of IDA at 12 months of age-does not fully correct earlier ID-mediated brain dysfunction, underscoring the need for low-cost, easily implementable adjunct therapies to iron to treat or prevent this dysfunction in high-risk populations. Supplementation with the essential nutrient choline lessens damage done to the developing hippocampus when given with iron in pre-clinical rodent models, and choline supplementation improves hippocampus-mediated memory and learning in 2-3-year-old children with Fetal Alcohol Spectrum Disorders, a condition associated with hippocampal damage and one for which ID is a component of the neuropathology. Choline has not been tested in children with IDA. Our overall aim is to conduct a randomized, placebo-controlled clinical trial to test whether nine months of daily choline supplementation along with standard iron therapy improves hippocampus-dependent neurobehavioral outcomes in Ugandan infants with IDA. METHODS: Three hundred 6-month-old infants with IDA who present to immunization clinics at Mulago and Kawempe National Referral Hospitals in Kampala, Uganda, will be randomized to iron plus choline or iron plus placebo. Iron (oral ferrous sulfate 2 mg/kg/day) will be given for the first 3 months of follow-up, and a dispersible tablet of choline (200 mg as choline bitartrate) or identical placebo will be given daily for all 9 months of follow-up. We will conduct neurobehavioral tests assessing hippocampus-specific memory and attention and global cognition at enrollment (when each infant is 6 months of age) and after 9 months of follow-up (when each infant is 15 months of age). DISCUSSION: If we find a neurobehavioral benefit when choline is given along with iron, choline could be added immediately to standard of care treatment for IDA. This low-cost intervention could safely mitigate the brain dysfunction of early-life ID that is often not diagnosed until the hippocampal critical window is closing, providing life-long benefit for both the individual and the economic and social prosperity of entire regions. TRIAL REGISTRATION: Clinical trials.gov NCT06527391. Registered on 24 July 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cusick SE, Mupere E, Bangirana P, et al. Supplemental choline to prevent and treat learning and memory deficits of early-life iron deficiency (The SupCHO Study): study protocol for a randomized, placebo-controlled trial in Ugandan infants with iron deficiency anemia. Trials. 2025. PMID: 41257751. doi:10.1186/s13063-025-09246-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。